NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Sponsor: Central Hospital, Nancy, France
Conditions: Covid-19
Interventions: 18F-FDG PET-CT
Countries: France
Patients with Covid-19 (Coronavirus disease 19) may experience multiple neurological symptoms . 18F-FDG PET-CT ( Positons EmissionTomography coupled with a Computer Tomography with flurodesoxyglucose labelled with fluor 18), which reflects neuronal glycolytic metabolism, shows early variations in neuronal function. Moreover the tropism of Covid-19 is essentially pulmonary and the hypothesis of this study is with 18F-FDG PET-CT it's possible to study the relationship between cerebral metabolism and the metabolism of pulmonary lesions following Covid-19 infection.
Sex: ALL
Age: 18 Years to 65 Years
Healthy volunteers: No
Study type: INTERVENTIONAL
Inclusion Criteria: * Patients aged between 18 and 65 years * Patient included in the Neurocog-Covid study (i.e. presenting a cognitive disorder that has been objectified on the neuropsychological assessment and having to undergo a cerebral MRI), * Patient who has received full information about the organization of the research and has given written informed consent (or a third person, independent of the investigator and sponsor, in the case of literacy disability), * Patient affiliated to or beneficiary of a social security plan Exclusion Criteria: * Women of childbearing age who do not have effective contraception. * Pregnant woman or nursing mother. * Persons referred to in Articles L. 1121-5, L. 1121-7 and L1121-8 of the Public Health Code. * Persons deprived of liberty by a judicial or administrative decision, persons undergoing psychiatric care pursuant to articles L. 3212-1 and L. 3213-1 * Contraindication to perform 18F-FDG PET-CT * Patients with a history of pre-Covid-19 psychiatric or chronic illness * Persons referred to in Articles L. 1121-5, L. 1121-7 and L1121-8 of the Public Health Code.
- Vandœuvre-lès-Nancy, France